Clinical Research Interview Question Part 2
โขDownload as PPTX, PDFโข
0 likesโข24 views
Embark on a comprehensive journey into the dynamic and critical realm of Clinical Research. This presentation serves as a guiding beacon for both novices and seasoned professionals, shedding light on the intricacies, significance, and evolving landscape of clinical research in advancing medical knowledge and improving patient outcomes.
Report
Share
Report
Share
Recommended
Cro perspectives
The document provides information about audits, inspections, and compliance from the perspective of a Contract Research Organization (CRO). It discusses what a CRO is and different types of CROs. It outlines the importance of having a structured compliance plan and ensuring compliance with Good Laboratory/Clinical/Manufacturing Practices, applicable rules, regulations, and guidelines. The document emphasizes that quality control, monitoring, auditing, and inspections are necessary to ensure compliance and pass regulatory inspections. It provides tips for sites on preparing for and handling inspections by regulatory authorities like the FDA.
NISHA YADAV ROLLNO. 2116102 PRESENTATION ON DEVELOPING CLINICAL TRIAL PROTOCO...
This document provides guidance on developing clinical trial protocols. It explains that every clinical trial begins with developing a protocol, which is a document that describes how the trial will be conducted. The protocol ensures safety and integrity. Key topics that should be included in a protocol according to guidelines are: background, objectives, study design, selection and treatment of subjects, assessment of efficacy and safety, statistics, ethics, and data handling. The protocol language should be understandable to physicians, nurses, reviewers, and ethics boards. Regulations provide requirements for protocols regarding application processes and responsibilities of sponsors, investigators, and ethics committees.
Quality regulation for biological products current and future
The document discusses current and future regulation of biological products by the Korea Food and Drug Administration (KFDA). It provides an overview of the KFDA's functions in regulating biological product quality, registration processes, relevant laws and guidelines. It also discusses specific areas like viral product control and challenges in regulating this emerging field.
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!Pristyn Research Solutions
This document provides a summary of common regulatory affairs job interview questions and answers. It begins with defining regulatory affairs and its goals of protecting human health, ensuring drug safety and efficacy, and ensuring accurate product information. It then discusses the roles of regulatory affairs professionals in interacting with regulatory agencies, preparing submissions, and ensuring compliance. The rest of the document provides answers to common interview questions about regulatory submissions, guidelines, authorities, and key concepts and legislation related to drug approval.ย
DEVELOPING THE CLINICAL TRIAL PROTOCOL | PPT
This document describes the detailed information of clinical trial protocol and protocol design. The protocol includes the key information of study designs. This document is downloaded as a PDF and viewed online.
Basic concepts about regulatory affairs
Regulatory affairs professionals act as the interface between the pharmaceutical industry and drug regulatory authorities. Their main goals are to protect human health, ensure drug safety and quality, and ensure accurate product information. Key roles include liaising with regulatory agencies, preparing regulatory submissions, and advising on regulatory requirements and guidelines. An investigational new drug (IND) application is filed with regulatory agencies to legally test an experimental drug in humans after preclinical testing. A new drug application (NDA) is filed to obtain approval to market a new drug, while an abbreviated new drug application (ANDA) is filed for generic drug approval based on demonstrating bioequivalence to an existing drug. Drug master files and active substance master files provide confidential manufacturing
COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS ASKED IN DRUG REGULATORY AFFAIRS ...
COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS ASKED IN DRUG REGULATORY AFFAIRS ...Pristyn Research Solutions
THESE ARE SOME COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS ASKED IN DRUG REGULATORY AFFAIRS INTERVIEW
FOR ENROLLMENT CALL US ON - 9028839789
https://pristynresearch.com/
MAIL ID - pristynresearch@gmail.com
FACEBOOK- https://www.facebook.com/pristynsolutions
INSTAGRAM- https://www.instagram.com/pristyn_res...
TWITTER- https://twitter.com/Pristynresearch
SLIDESHARE- https://www.slideshare.net/azherkhan5916
LINKEDIN- https://www.linkedin.com/in/pristyn-research-191072119/
ADDRESS-
1) Parmar Trade Centre, A-wing,105/106, Sadhu Vaswani Chowk, Pune, 411001. Email: info@pristynresearch.com Phone: 09028839789
2)T-21/4 ,Opposite To Expert Global, Garware Stadium Road , Software Technology Park of India(STPI), MIDC, Aurangabad-431001. Email: info@pristynresearch.com Call us: 09607709586
ย
Nda
This document provides an overview of the New Drug Application (NDA) process. It discusses what an NDA is, its goals, forms, contents, guidance documents, submission process, and review/approval. Key points include that an NDA is required for marketing approval of new drugs in the US and contains data from clinical trials demonstrating safety and effectiveness. The review process evaluates these factors and can result in approval or refusal. Guidance documents provide guidelines for preparing and submitting the various sections of an NDA to the FDA.
Recommended
Cro perspectives
The document provides information about audits, inspections, and compliance from the perspective of a Contract Research Organization (CRO). It discusses what a CRO is and different types of CROs. It outlines the importance of having a structured compliance plan and ensuring compliance with Good Laboratory/Clinical/Manufacturing Practices, applicable rules, regulations, and guidelines. The document emphasizes that quality control, monitoring, auditing, and inspections are necessary to ensure compliance and pass regulatory inspections. It provides tips for sites on preparing for and handling inspections by regulatory authorities like the FDA.
NISHA YADAV ROLLNO. 2116102 PRESENTATION ON DEVELOPING CLINICAL TRIAL PROTOCO...
This document provides guidance on developing clinical trial protocols. It explains that every clinical trial begins with developing a protocol, which is a document that describes how the trial will be conducted. The protocol ensures safety and integrity. Key topics that should be included in a protocol according to guidelines are: background, objectives, study design, selection and treatment of subjects, assessment of efficacy and safety, statistics, ethics, and data handling. The protocol language should be understandable to physicians, nurses, reviewers, and ethics boards. Regulations provide requirements for protocols regarding application processes and responsibilities of sponsors, investigators, and ethics committees.
Quality regulation for biological products current and future
The document discusses current and future regulation of biological products by the Korea Food and Drug Administration (KFDA). It provides an overview of the KFDA's functions in regulating biological product quality, registration processes, relevant laws and guidelines. It also discusses specific areas like viral product control and challenges in regulating this emerging field.
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!Pristyn Research Solutions
This document provides a summary of common regulatory affairs job interview questions and answers. It begins with defining regulatory affairs and its goals of protecting human health, ensuring drug safety and efficacy, and ensuring accurate product information. It then discusses the roles of regulatory affairs professionals in interacting with regulatory agencies, preparing submissions, and ensuring compliance. The rest of the document provides answers to common interview questions about regulatory submissions, guidelines, authorities, and key concepts and legislation related to drug approval.ย
DEVELOPING THE CLINICAL TRIAL PROTOCOL | PPT
This document describes the detailed information of clinical trial protocol and protocol design. The protocol includes the key information of study designs. This document is downloaded as a PDF and viewed online.
Basic concepts about regulatory affairs
Regulatory affairs professionals act as the interface between the pharmaceutical industry and drug regulatory authorities. Their main goals are to protect human health, ensure drug safety and quality, and ensure accurate product information. Key roles include liaising with regulatory agencies, preparing regulatory submissions, and advising on regulatory requirements and guidelines. An investigational new drug (IND) application is filed with regulatory agencies to legally test an experimental drug in humans after preclinical testing. A new drug application (NDA) is filed to obtain approval to market a new drug, while an abbreviated new drug application (ANDA) is filed for generic drug approval based on demonstrating bioequivalence to an existing drug. Drug master files and active substance master files provide confidential manufacturing
COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS ASKED IN DRUG REGULATORY AFFAIRS ...
COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS ASKED IN DRUG REGULATORY AFFAIRS ...Pristyn Research Solutions
THESE ARE SOME COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS ASKED IN DRUG REGULATORY AFFAIRS INTERVIEW
FOR ENROLLMENT CALL US ON - 9028839789
https://pristynresearch.com/
MAIL ID - pristynresearch@gmail.com
FACEBOOK- https://www.facebook.com/pristynsolutions
INSTAGRAM- https://www.instagram.com/pristyn_res...
TWITTER- https://twitter.com/Pristynresearch
SLIDESHARE- https://www.slideshare.net/azherkhan5916
LINKEDIN- https://www.linkedin.com/in/pristyn-research-191072119/
ADDRESS-
1) Parmar Trade Centre, A-wing,105/106, Sadhu Vaswani Chowk, Pune, 411001. Email: info@pristynresearch.com Phone: 09028839789
2)T-21/4 ,Opposite To Expert Global, Garware Stadium Road , Software Technology Park of India(STPI), MIDC, Aurangabad-431001. Email: info@pristynresearch.com Call us: 09607709586
ย
Nda
This document provides an overview of the New Drug Application (NDA) process. It discusses what an NDA is, its goals, forms, contents, guidance documents, submission process, and review/approval. Key points include that an NDA is required for marketing approval of new drugs in the US and contains data from clinical trials demonstrating safety and effectiveness. The review process evaluates these factors and can result in approval or refusal. Guidance documents provide guidelines for preparing and submitting the various sections of an NDA to the FDA.
Different Types of Regulatory Documents
Regulatory documents are required by health authorities before approval of new drugs, devices, or biologics. These documents include protocols, clinical study reports, investigator brochures, common technical documents, informed consent forms, and risk management plans. Protocols describe the study procedures and analysis plans. Clinical study reports integrate full study reports according to ICH guidelines. Investigator brochures provide safety information to investigators. Common technical documents assemble quality, safety, and efficacy data for regulatory submissions. Informed consent forms provide study information for participants. Risk management plans describe safety profiles and risk minimization plans.
IND, NDA, ANDA, SNDA
The document discusses Investigational New Drug Applications (INDs), New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Supplemental New Drug Applications (SNDAs). It provides details on the purpose and requirements of each application type, including necessary contents, guidelines, and the laws and regulations that govern the FDA drug approval process.
Clinical research management slide
This presentation discusses various topics related to clinical research management including:
- Preparation of clinical studies according to ICH guidelines.
- The difference between audits and inspections, who conducts them, and what they audit.
- Monitoring clinical studies to ensure adherence to protocols, SOPs, and regulations.
- Pharmacovigilance including adverse event reporting procedures.
- Documentation requirements for clinical research.
- Budgeting considerations for clinical trials including personnel, technology, data management.
- Vendor management activities like contracting, governance, and relationship management.
Therapeutic Goods Evaluation Panel Roadshow - Overview of Clinical Evaluations
The document provides an overview of external evaluations of prescription medicines conducted by the Therapeutic Goods Administration (TGA) in Australia. It discusses the role of the TGA in regulating medicines and evaluating clinical data in applications. Clinical evaluators within the TGA are responsible for independently assessing application dossiers, summarizing the clinical data, and writing Clinical Evaluation Reports which make recommendations regarding approval and product information. The reports follow a template and guidelines to ensure a high-quality and rigorous evaluation is conducted.
Pharmacovigilance audit
A pharmacovigilance audit involves several key steps: (1) opening meetings with relevant personnel, (2) document reviews and interviews to evaluate processes for safety data collection, case assessment, and reporting, (3) analyzing data to identify potential safety signals, and (4) closing meetings to discuss preliminary findings. The audit aims to verify that the pharmacovigilance system meets legal requirements for drug safety monitoring and ensure any issues from previous inspections have been addressed. Regular audits are important for regulatory compliance and identifying areas for improvement in pharmacovigilance practices.
Investigational New Drug Application
Investigational new drug application must be submitted after discovering a new drug and before beginning of clinical trials. Here given a brief note on the topic.The topics included are types of IND, criteria for application, Information in IND application, resources for IND application, laws.regulations, policies and procedures, IND forms and instructions, IND content requirements and review of IND
GCP for Investigators by Valentyna
The document discusses clinical trials and good clinical practice (GCP) guidelines. It provides definitions and explanations of key concepts.
Specifically, it defines a clinical trial as an investigation in human subjects to discover or verify the effects of an investigational product. It describes GCP as international standards for clinical trial conduct that ensure data credibility and protect subject rights. The guidelines aim to harmonize standards across regions through organizations like the International Council for Harmonization.
The document then outlines investigator responsibilities in areas like trial preparation, conduct, and closure to ensure compliance with GCP standards and protect subject safety and data integrity.
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
The document discusses the process for product registration and drug approval in the United States. All new drug products must complete a registration process with the FDA to ensure safety and efficacy. This involves submitting a New Drug Application (NDA) containing clinical and manufacturing data and information. The NDA goes through a review process by FDA teams with expertise in technical areas. The review determines if the drug is approved for marketing in the United States.
Quality and Regulatory Affairs
The document discusses the regulatory IND (Investigational New Drug) process for bringing a new drug to market in the United States. It outlines the requirements for submitting an IND application to the FDA, including non-clinical data from animal and early human studies demonstrating safety and effectiveness. Key components that must be addressed are chemistry and manufacturing controls, pharmacology and toxicology data, clinical protocols, and plans for interaction and meetings with FDA regulators during the process.
Regulatory Inspections in Clinical Trials
Regulatory inspections are important to evaluate clinical trial data integrity and patient safety. Health authorities like the FDA and EMA may conduct inspections whenever required to inspect clinical trial sites and evaluate sponsor quality systems. Inspections involve touring facilities and reviewing documents like informed consents, safety reporting, and drug administration records. Common findings include protocol noncompliance, inaccurate records, and issues with informed consent and adverse event reporting. Inspections help ensure trials are conducted properly and help improve compliance.
The regulation of complementary medicines
The Therapeutic Goods Administration (TGA) regulates complementary medicines in Australia using a risk-based, two-tiered system. Lower risk listed medicines can be marketed with minimal pre-market evaluation, while higher risk registered medicines require pre-market assessment of quality, safety and efficacy. The TGA oversees post-market monitoring and compliance reviews to ensure that medicines meet regulatory requirements. Guidance materials provide information on evidence requirements and the different pathways for listed and registered complementary medicines.
Ma p ps
This document outlines the policies and procedures for the Division of Filing Review to conduct a filing review of an abbreviated new drug application. It provides background on FDA's evaluation of each ANDA submission individually to determine if it is sufficiently complete to permit substantive review. It details the responsibilities and procedures of the filing review, which includes reviewing each module of the ANDA submission for required information and identifying any deficiencies. The filing review will determine whether to receive the ANDA, issue an information request, or refuse-to-receive the application based on the presence of major or minor deficiencies.
summary report of inspections of clinical trials conducted from April 2004 to...
This document summarizes Health Canada inspections of clinical trials conducted from 2004 to 2011. During this period, 329 inspections found 3148 observations of non-compliance, mostly related to quality systems/procedures and record keeping. 92% of inspections were rated compliant and 8% non-compliant. Common deficiencies included lack of standard operating procedures, inadequate documentation and personnel training. The report aims to increase awareness of regulatory requirements and improve compliance for protecting clinical trial participants.
NDA.pptx
For decades, the regulation and control of new drugs in the United States has been based on the New Drug Application (NDA). Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization. The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S. The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA.
NDA.pptx
The document provides an overview of the New Drug Application (NDA) process. It discusses that an NDA is required for approval to market a new drug in the US. The goals of an NDA are to demonstrate a drug's safety, efficacy, appropriate labeling, and quality manufacturing. An NDA contains extensive data from non-clinical and clinical trials. It follows a common technical document format and is reviewed by the FDA to determine if the drug's benefits outweigh the risks for approval.
ICH GCP GUIDELINES FOR CONDUCT OF TRIAL
The document discusses the ICH GCP guidelines for conducting clinical trials. The key points are:
1) GCP guidelines provide ethical and quality standards for clinical trial conduct to protect subject safety and ensure data credibility.
2) The guidelines establish responsibilities for investigators, sponsors, and ethics committees to follow principles where subject welfare prevails over science and trials must be scientifically sound.
3) The ICH facilitates harmonization across countries/regions to streamline drug development and avoid duplicative trials through consensus guidelines.
Regulatory affairs-Introduction to CTD
Regulatory affairs is the bridge between pharmaceutical companies and government regulatory agencies. It involves all activities related to drugs, including research, clinical trials, manufacturing, registration, distribution, pricing, advertising, and post-marketing surveillance. Regulatory dossiers contain all required technical data and documentation needed to obtain approval to market a drug in a given country or region. Common formats include the Common Technical Document for Europe, US, and other markets and Form 44 for India. Compliance with good practices and local regulations is essential for regulatory approval.
Ich Fda Socra 09 2007
- The document compares the FDA regulations for clinical trials to the International Conference on Harmonization's (ICH) Good Clinical Practice (GCP) guidelines.
- There are some differences between the two, such as ICH requiring more documentation of trial procedures and delegation of duties, while FDA regulations are less specific.
- Overall ICH GCP guidelines facilitate international harmonization and acceptance of clinical trial data between the US, EU, and Japan. Compliance with ICH GCP helps assure rights and safety of trial subjects.
Audit and Inspection in Clinical Trial
This document discusses audits and inspections in clinical trials. It defines an audit as a systematic examination of trial activities and documents to determine compliance, while an inspection involves a regulatory review of documents, facilities, and resources related to a trial. The key differences between audits and inspections are that audits are conducted internally by sponsors or CROs, while inspections are done by regulatory authorities. Routine audits ensure compliance, while for-cause audits investigate non-compliance issues. Audits and inspections evaluate areas like personnel, trial conduct, documentation, drug accountability, and computer systems. Proper preparation and responding to document requests within time limits are important for audits and inspections.
Audit and inspection by madhukar thagnar
This document discusses clinical trial audits and inspections. It defines an audit as a systematic and independent examination of trial activities and documents to determine compliance, while an inspection involves a regulatory review of documents, facilities, and resources related to a clinical trial. The key differences between audits and inspections are that audits are conducted internally by sponsors or CROs, while inspections are done by regulatory authorities. The document outlines what should be audited, including organizational structure, investigational products, IRB/EC activities, essential documents, laboratories, and computer systems. It provides guidance on pre-audit preparation and procedures during and after an audit or inspection.
Role of Drug Regulatory agencies in Clinical Research.
Drug regulatory agencies play a pivotal role in overseeing and regulating clinical research to ensure the safety, efficacy, and quality of pharmaceutical products. Their primary responsibility is to protect public health by evaluating the data generated from clinical trials and determining whether a drug can be approved for marketing and use in patients. Here are some key roles of drug regulatory agencies in clinical research:
Approval and Oversight of Clinical Trials: Regulatory agencies review and approve clinical trial protocols, ensuring that they adhere to ethical and scientific standards. They assess the design, methodology, and objectives of trials to ensure patient safety and the reliability of data generated.
Regulatory Guidance and Standards: These agencies provide guidance and establish regulations governing the conduct of clinical trials, including Good Clinical Practice (GCP) guidelines, which outline standards for trial design, conduct, monitoring, and reporting.
Review and Evaluation of Data: Regulatory agencies review the data collected from clinical trials to assess the safety and efficacy of investigational drugs. They evaluate study results, adverse events, and other relevant information to make informed decisions about drug approval.
Drug Approval and Labeling: Based on the evaluation of clinical trial data, regulatory agencies decide whether to approve a drug for marketing and use. They also determine the appropriate labeling, including indications, dosages, contraindications, and warnings, to ensure safe and effective use by healthcare professionals and patients.
Post-Marketing Surveillance: Regulatory agencies continue to monitor the safety and effectiveness of approved drugs through post-marketing surveillance programs. They collect and analyze real-world data on adverse events and drug utilization to identify potential risks and take appropriate regulatory actions if safety concerns arise.
Enforcement of Regulations: Regulatory agencies enforce compliance with regulatory requirements and take enforcement actions against sponsors, investigators, or manufacturers who fail to adhere to ethical or regulatory standards in clinical research.
International Collaboration: Many regulatory agencies collaborate with counterparts in other countries to harmonize regulatory standards, exchange information, and streamline the drug approval process, facilitating global drug development and access to new therapies.
Data Privacy and consent management .. .
Data privacy and consent management are critical aspects of ensuring that individuals' personal information is handled responsibly and ethically, particularly in healthcare settings where sensitive medical data is involved. Data privacy refers to the protection of personal information from unauthorized access, use, or disclosure, while consent management involves obtaining and managing individuals' permissions for the collection, storage, and processing of their data.
In healthcare, patients entrust providers with their sensitive medical information, expecting that it will be kept confidential and used only for legitimate purposes related to their care. Robust data privacy measures include encryption, access controls, and anonymization techniques to safeguard patient data from unauthorized access or breaches. Additionally, healthcare organizations must adhere to regulatory standards such as HIPAA in the United States or GDPR in the European Union, which outline specific requirements for the protection of patient information and impose penalties for non-compliance.
Consent management plays a crucial role in ensuring that individuals have control over how their data is used. Patients should be informed about the purposes for which their data will be collected and processed, as well as any potential risks or benefits associated with its use. Obtaining informed consent involves providing individuals with clear and transparent information about their privacy rights and giving them the opportunity to consent to or decline the use of their data for specific purposes. Consent management systems help healthcare organizations track and manage patients' consent preferences, ensuring that data is used in accordance with their wishes and legal requirements.
Effective data privacy and consent management practices not only protect individuals' privacy rights but also foster trust and transparency in healthcare relationships. By implementing robust security measures, respecting patients' autonomy, and promoting informed decision-making, healthcare organizations can uphold the principles of data privacy and consent while leveraging data responsibly to improve patient care and outcomes.
More Related Content
Similar to Clinical Research Interview Question Part 2
Different Types of Regulatory Documents
Regulatory documents are required by health authorities before approval of new drugs, devices, or biologics. These documents include protocols, clinical study reports, investigator brochures, common technical documents, informed consent forms, and risk management plans. Protocols describe the study procedures and analysis plans. Clinical study reports integrate full study reports according to ICH guidelines. Investigator brochures provide safety information to investigators. Common technical documents assemble quality, safety, and efficacy data for regulatory submissions. Informed consent forms provide study information for participants. Risk management plans describe safety profiles and risk minimization plans.
IND, NDA, ANDA, SNDA
The document discusses Investigational New Drug Applications (INDs), New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Supplemental New Drug Applications (SNDAs). It provides details on the purpose and requirements of each application type, including necessary contents, guidelines, and the laws and regulations that govern the FDA drug approval process.
Clinical research management slide
This presentation discusses various topics related to clinical research management including:
- Preparation of clinical studies according to ICH guidelines.
- The difference between audits and inspections, who conducts them, and what they audit.
- Monitoring clinical studies to ensure adherence to protocols, SOPs, and regulations.
- Pharmacovigilance including adverse event reporting procedures.
- Documentation requirements for clinical research.
- Budgeting considerations for clinical trials including personnel, technology, data management.
- Vendor management activities like contracting, governance, and relationship management.
Therapeutic Goods Evaluation Panel Roadshow - Overview of Clinical Evaluations
The document provides an overview of external evaluations of prescription medicines conducted by the Therapeutic Goods Administration (TGA) in Australia. It discusses the role of the TGA in regulating medicines and evaluating clinical data in applications. Clinical evaluators within the TGA are responsible for independently assessing application dossiers, summarizing the clinical data, and writing Clinical Evaluation Reports which make recommendations regarding approval and product information. The reports follow a template and guidelines to ensure a high-quality and rigorous evaluation is conducted.
Pharmacovigilance audit
A pharmacovigilance audit involves several key steps: (1) opening meetings with relevant personnel, (2) document reviews and interviews to evaluate processes for safety data collection, case assessment, and reporting, (3) analyzing data to identify potential safety signals, and (4) closing meetings to discuss preliminary findings. The audit aims to verify that the pharmacovigilance system meets legal requirements for drug safety monitoring and ensure any issues from previous inspections have been addressed. Regular audits are important for regulatory compliance and identifying areas for improvement in pharmacovigilance practices.
Investigational New Drug Application
Investigational new drug application must be submitted after discovering a new drug and before beginning of clinical trials. Here given a brief note on the topic.The topics included are types of IND, criteria for application, Information in IND application, resources for IND application, laws.regulations, policies and procedures, IND forms and instructions, IND content requirements and review of IND
GCP for Investigators by Valentyna
The document discusses clinical trials and good clinical practice (GCP) guidelines. It provides definitions and explanations of key concepts.
Specifically, it defines a clinical trial as an investigation in human subjects to discover or verify the effects of an investigational product. It describes GCP as international standards for clinical trial conduct that ensure data credibility and protect subject rights. The guidelines aim to harmonize standards across regions through organizations like the International Council for Harmonization.
The document then outlines investigator responsibilities in areas like trial preparation, conduct, and closure to ensure compliance with GCP standards and protect subject safety and data integrity.
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
The document discusses the process for product registration and drug approval in the United States. All new drug products must complete a registration process with the FDA to ensure safety and efficacy. This involves submitting a New Drug Application (NDA) containing clinical and manufacturing data and information. The NDA goes through a review process by FDA teams with expertise in technical areas. The review determines if the drug is approved for marketing in the United States.
Quality and Regulatory Affairs
The document discusses the regulatory IND (Investigational New Drug) process for bringing a new drug to market in the United States. It outlines the requirements for submitting an IND application to the FDA, including non-clinical data from animal and early human studies demonstrating safety and effectiveness. Key components that must be addressed are chemistry and manufacturing controls, pharmacology and toxicology data, clinical protocols, and plans for interaction and meetings with FDA regulators during the process.
Regulatory Inspections in Clinical Trials
Regulatory inspections are important to evaluate clinical trial data integrity and patient safety. Health authorities like the FDA and EMA may conduct inspections whenever required to inspect clinical trial sites and evaluate sponsor quality systems. Inspections involve touring facilities and reviewing documents like informed consents, safety reporting, and drug administration records. Common findings include protocol noncompliance, inaccurate records, and issues with informed consent and adverse event reporting. Inspections help ensure trials are conducted properly and help improve compliance.
The regulation of complementary medicines
The Therapeutic Goods Administration (TGA) regulates complementary medicines in Australia using a risk-based, two-tiered system. Lower risk listed medicines can be marketed with minimal pre-market evaluation, while higher risk registered medicines require pre-market assessment of quality, safety and efficacy. The TGA oversees post-market monitoring and compliance reviews to ensure that medicines meet regulatory requirements. Guidance materials provide information on evidence requirements and the different pathways for listed and registered complementary medicines.
Ma p ps
This document outlines the policies and procedures for the Division of Filing Review to conduct a filing review of an abbreviated new drug application. It provides background on FDA's evaluation of each ANDA submission individually to determine if it is sufficiently complete to permit substantive review. It details the responsibilities and procedures of the filing review, which includes reviewing each module of the ANDA submission for required information and identifying any deficiencies. The filing review will determine whether to receive the ANDA, issue an information request, or refuse-to-receive the application based on the presence of major or minor deficiencies.
summary report of inspections of clinical trials conducted from April 2004 to...
This document summarizes Health Canada inspections of clinical trials conducted from 2004 to 2011. During this period, 329 inspections found 3148 observations of non-compliance, mostly related to quality systems/procedures and record keeping. 92% of inspections were rated compliant and 8% non-compliant. Common deficiencies included lack of standard operating procedures, inadequate documentation and personnel training. The report aims to increase awareness of regulatory requirements and improve compliance for protecting clinical trial participants.
NDA.pptx
For decades, the regulation and control of new drugs in the United States has been based on the New Drug Application (NDA). Since 1938, every new drug has been the subject of an approved NDA before U.S. commercialization. The NDA application is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S. The data gathered during the animal studies and human clinical trials of an Investigational New Drug (IND) become part of the NDA.
NDA.pptx
The document provides an overview of the New Drug Application (NDA) process. It discusses that an NDA is required for approval to market a new drug in the US. The goals of an NDA are to demonstrate a drug's safety, efficacy, appropriate labeling, and quality manufacturing. An NDA contains extensive data from non-clinical and clinical trials. It follows a common technical document format and is reviewed by the FDA to determine if the drug's benefits outweigh the risks for approval.
ICH GCP GUIDELINES FOR CONDUCT OF TRIAL
The document discusses the ICH GCP guidelines for conducting clinical trials. The key points are:
1) GCP guidelines provide ethical and quality standards for clinical trial conduct to protect subject safety and ensure data credibility.
2) The guidelines establish responsibilities for investigators, sponsors, and ethics committees to follow principles where subject welfare prevails over science and trials must be scientifically sound.
3) The ICH facilitates harmonization across countries/regions to streamline drug development and avoid duplicative trials through consensus guidelines.
Regulatory affairs-Introduction to CTD
Regulatory affairs is the bridge between pharmaceutical companies and government regulatory agencies. It involves all activities related to drugs, including research, clinical trials, manufacturing, registration, distribution, pricing, advertising, and post-marketing surveillance. Regulatory dossiers contain all required technical data and documentation needed to obtain approval to market a drug in a given country or region. Common formats include the Common Technical Document for Europe, US, and other markets and Form 44 for India. Compliance with good practices and local regulations is essential for regulatory approval.
Ich Fda Socra 09 2007
- The document compares the FDA regulations for clinical trials to the International Conference on Harmonization's (ICH) Good Clinical Practice (GCP) guidelines.
- There are some differences between the two, such as ICH requiring more documentation of trial procedures and delegation of duties, while FDA regulations are less specific.
- Overall ICH GCP guidelines facilitate international harmonization and acceptance of clinical trial data between the US, EU, and Japan. Compliance with ICH GCP helps assure rights and safety of trial subjects.
Audit and Inspection in Clinical Trial
This document discusses audits and inspections in clinical trials. It defines an audit as a systematic examination of trial activities and documents to determine compliance, while an inspection involves a regulatory review of documents, facilities, and resources related to a trial. The key differences between audits and inspections are that audits are conducted internally by sponsors or CROs, while inspections are done by regulatory authorities. Routine audits ensure compliance, while for-cause audits investigate non-compliance issues. Audits and inspections evaluate areas like personnel, trial conduct, documentation, drug accountability, and computer systems. Proper preparation and responding to document requests within time limits are important for audits and inspections.
Audit and inspection by madhukar thagnar
This document discusses clinical trial audits and inspections. It defines an audit as a systematic and independent examination of trial activities and documents to determine compliance, while an inspection involves a regulatory review of documents, facilities, and resources related to a clinical trial. The key differences between audits and inspections are that audits are conducted internally by sponsors or CROs, while inspections are done by regulatory authorities. The document outlines what should be audited, including organizational structure, investigational products, IRB/EC activities, essential documents, laboratories, and computer systems. It provides guidance on pre-audit preparation and procedures during and after an audit or inspection.
Similar to Clinical Research Interview Question Part 2 (20)
Therapeutic Goods Evaluation Panel Roadshow - Overview of Clinical Evaluations
Therapeutic Goods Evaluation Panel Roadshow - Overview of Clinical Evaluations
ย
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
akshay regulatory seminar 1 productregistrationanddrugapprovalprocessinus.ppt
ย
summary report of inspections of clinical trials conducted from April 2004 to...
summary report of inspections of clinical trials conducted from April 2004 to...
ย
More from ClinosolIndia
Role of Drug Regulatory agencies in Clinical Research.
Drug regulatory agencies play a pivotal role in overseeing and regulating clinical research to ensure the safety, efficacy, and quality of pharmaceutical products. Their primary responsibility is to protect public health by evaluating the data generated from clinical trials and determining whether a drug can be approved for marketing and use in patients. Here are some key roles of drug regulatory agencies in clinical research:
Approval and Oversight of Clinical Trials: Regulatory agencies review and approve clinical trial protocols, ensuring that they adhere to ethical and scientific standards. They assess the design, methodology, and objectives of trials to ensure patient safety and the reliability of data generated.
Regulatory Guidance and Standards: These agencies provide guidance and establish regulations governing the conduct of clinical trials, including Good Clinical Practice (GCP) guidelines, which outline standards for trial design, conduct, monitoring, and reporting.
Review and Evaluation of Data: Regulatory agencies review the data collected from clinical trials to assess the safety and efficacy of investigational drugs. They evaluate study results, adverse events, and other relevant information to make informed decisions about drug approval.
Drug Approval and Labeling: Based on the evaluation of clinical trial data, regulatory agencies decide whether to approve a drug for marketing and use. They also determine the appropriate labeling, including indications, dosages, contraindications, and warnings, to ensure safe and effective use by healthcare professionals and patients.
Post-Marketing Surveillance: Regulatory agencies continue to monitor the safety and effectiveness of approved drugs through post-marketing surveillance programs. They collect and analyze real-world data on adverse events and drug utilization to identify potential risks and take appropriate regulatory actions if safety concerns arise.
Enforcement of Regulations: Regulatory agencies enforce compliance with regulatory requirements and take enforcement actions against sponsors, investigators, or manufacturers who fail to adhere to ethical or regulatory standards in clinical research.
International Collaboration: Many regulatory agencies collaborate with counterparts in other countries to harmonize regulatory standards, exchange information, and streamline the drug approval process, facilitating global drug development and access to new therapies.
Data Privacy and consent management .. .
Data privacy and consent management are critical aspects of ensuring that individuals' personal information is handled responsibly and ethically, particularly in healthcare settings where sensitive medical data is involved. Data privacy refers to the protection of personal information from unauthorized access, use, or disclosure, while consent management involves obtaining and managing individuals' permissions for the collection, storage, and processing of their data.
In healthcare, patients entrust providers with their sensitive medical information, expecting that it will be kept confidential and used only for legitimate purposes related to their care. Robust data privacy measures include encryption, access controls, and anonymization techniques to safeguard patient data from unauthorized access or breaches. Additionally, healthcare organizations must adhere to regulatory standards such as HIPAA in the United States or GDPR in the European Union, which outline specific requirements for the protection of patient information and impose penalties for non-compliance.
Consent management plays a crucial role in ensuring that individuals have control over how their data is used. Patients should be informed about the purposes for which their data will be collected and processed, as well as any potential risks or benefits associated with its use. Obtaining informed consent involves providing individuals with clear and transparent information about their privacy rights and giving them the opportunity to consent to or decline the use of their data for specific purposes. Consent management systems help healthcare organizations track and manage patients' consent preferences, ensuring that data is used in accordance with their wishes and legal requirements.
Effective data privacy and consent management practices not only protect individuals' privacy rights but also foster trust and transparency in healthcare relationships. By implementing robust security measures, respecting patients' autonomy, and promoting informed decision-making, healthcare organizations can uphold the principles of data privacy and consent while leveraging data responsibly to improve patient care and outcomes.
Clinical data security and Integrity in Clinical Research
Clinical data security and integrity are paramount in maintaining patient confidentiality, protecting sensitive medical information, and ensuring the reliability of healthcare data. Security measures encompass various strategies and technologies aimed at safeguarding clinical data from unauthorized access, breaches, or manipulation.
Encryption techniques, access controls, and secure authentication mechanisms are commonly employed to restrict access to patient records and prevent unauthorized individuals from viewing or altering sensitive data. Additionally, robust network security protocols, such as firewalls and intrusion detection systems, help safeguard against external threats and cyberattacks targeting healthcare systems.
Pharmacovigilance in Patriatics and Geriatrics
Pharmacovigilance in pediatrics and geriatrics is of paramount importance due to the unique physiological and pharmacokinetic characteristics of these populations. In pediatrics, factors such as rapid growth, organ maturation, and differences in drug metabolism can influence the safety and efficacy of medications. Therefore, monitoring for adverse drug reactions (ADRs), including both known and unexpected effects, is crucial in ensuring the safe use of drugs in children. Additionally, since pediatric patients often receive off-label or unlicensed medications due to limited clinical trials in this population, pharmacovigilance efforts play a critical role in gathering real-world data to inform pediatric drug use.
Presenting- Signal mining in Pharmacovigilance
Signal mining in pharmacovigilance involves the systematic analysis of large datasets to identify potential safety signals associated with medications. It encompasses a variety of computational and statistical methods aimed at detecting patterns or trends that may indicate previously unrecognized adverse drug reactions (ADRs). Signal mining relies on data from sources such as spontaneous reporting systems, electronic health records, clinical trials, and medical literature. Advanced algorithms and data mining techniques, including disproportionality analysis, Bayesian data mining, and machine learning, are employed to sift through vast amounts of data to uncover potential signals of concern. These signals are then subjected to further evaluation to determine their clinical relevance and potential impact on patient safety. By leveraging the power of big data and analytics, signal mining plays a crucial role in enhancing pharmacovigilance efforts, enabling proactive identification and mitigation of medication-related risks, and ultimately contributing to improved patient care and drug safety.
Patient centered Pharmacovigilance .. .
Patient-centered pharmacovigilance represents a pivotal shift in the landscape of healthcare, emphasizing the active involvement of patients in the monitoring and reporting of adverse drug reactions. Unlike traditional pharmacovigilance, which primarily relies on healthcare professionals to identify and document adverse events, this approach recognizes patients as critical stakeholders in ensuring medication safety. By empowering patients to share their experiences, concerns, and observations regarding medication effects, whether positive or negative, healthcare systems can gain a comprehensive understanding of drug safety and efficacy in real-world settings. Patient-centered pharmacovigilance fosters a collaborative partnership between patients, healthcare providers, and regulatory agencies, promoting transparency, accountability, and ultimately, better patient outcomes. Through increased patient engagement and the utilization of patient-reported data, this approach enables healthcare systems to identify potential safety issues earlier, tailor treatment strategies to individual needs, and enhance overall drug safety surveillance efforts.
Introduction to Blogs, Presentations and Review Articles- Noorush Shifa Nizami
Blogs, presentations, and review articles stand as dynamic mediums, each with its unique power to engage, inform, and influence. Blogs, the conversational storytellers; presentations, the visual orchestrators; and review articles, the comprehensive knowledge curators, collectively play pivotal roles in shaping how we share, learn, and explore diverse subjects. This exploration delves into the distinct characteristics and purposes of these forms of communication, unveiling the art of effective expression and knowledge sharing in the digital age.
Patient-Centric Approaches in Precision Medicine Trials: Strategies for Success
Precision medicine, with its focus on tailoring medical treatment to the individual characteristics of each patient, has ushered in a new era in healthcare. Within this paradigm, clinical trials play a pivotal role in testing and validating targeted therapies. This article explores the importance of adopting patient-centric approaches in precision medicine trials and outlines strategies to enhance their success. By prioritizing patient engagement, leveraging digital technologies, and fostering collaborative partnerships, precision medicine trials can not only advance scientific understanding but also ensure that patient perspectives and experiences are integral to the research process.
Collaborative Initiatives: How Patient Advocacy Groups Contribute to the Succ...
Collaborative initiatives involving patient advocacy groups play a crucial role in advancing the success of precision medicine. Precision medicine, also known as personalized medicine, tailors medical treatment and interventions to the characteristics of each patient, considering factors such as genetic makeup, lifestyle, and environment. Patient advocacy groups contribute to the success of precision medicine in several ways:
Raising Awareness and Education:
Patient advocacy groups are instrumental in raising awareness about precision medicine among their communities.
They provide education and resources to patients, caregivers, and the general public, promoting a better understanding of the benefits and implications of precision medicine.
Patient Empowerment:
Advocacy groups empower patients by providing them with information about their conditions and treatment options.
They help patients understand the importance of participating in precision medicine initiatives, including clinical trials and genetic testing.
Supporting Research and Development:
Patient advocacy groups often collaborate with researchers and industry stakeholders to support the development of targeted therapies and diagnostics.
By actively participating in research initiatives, advocacy groups contribute to the identification of genetic markers, biomarkers, and other factors that influence treatment response.
Influencing Policy and Regulation:
Advocacy groups advocate for policies that support the advancement of precision medicine.
They work to ensure that regulations promote patient access to personalized treatments and protect patient rights, privacy, and data security.
Fostering Collaboration:
Patient advocacy groups facilitate collaboration among patients, researchers, healthcare providers, and industry partners.
They create platforms for sharing information, experiences, and best practices, fostering a collaborative environment that accelerates progress in precision medicine.
Clinical Trial Recruitment:
Advocacy groups play a crucial role in recruiting patients for clinical trials related to precision medicine.
Their engagement helps ensure diverse and representative participant populations, leading to more robust and applicable research outcomes.
Feedback and Patient-Centric Approaches:
Advocacy groups provide valuable feedback on the patient experience, preferences, and priorities.
This patient-centric approach helps researchers and healthcare professionals tailor precision medicine strategies to better meet the needs and expectations of the individuals they serve.
Championing Access to Treatments:
Patient advocacy groups work to improve patient access to precision medicine treatments.
They advocate for affordable and equitable access to innovative therapies, ensuring that the benefits of precision medicine are accessible to a broader population.
In summary, patient advocacy groups play a multifaceted role in advancing precision medicine by fostering awareness,
Ethical Dilemmas in Precision Medicine: Navigating the Intersection of Scienc...
The Ethical dilemmas in precision medicine arise from balancing the potential benefits of tailored treatments with concerns about privacy, consent, equity, and the implications of genetic information. These Dilemmas include issues around informed consent for data sharing, ensuring equitable access to precision medicine technologies, and safeguarding against discrimination based on Information. The potential for misuse or unintended consequences further complicate the ethical landscape of precision medicine. The Precision medicine widely used in Data Integration, Biomarkers, Targeted Therapies, predictive modeling, Clinical Decision Support. Precision Medicine improves the Patient outcomes, enhancing treatment efficacy, and reducing healthcare costs by minimizing trial and error in treatment selection. The precision medicine also raises Ethical legal and social complications related to data privacy, consent and equitable access and the potential for Discrimination based on information.
Regulatory Considerations in Precision Medicine: Navigating the Approval Process
Precision medicine, with its focus on tailoring medical treatments to individual characteristics, presents unique regulatory challenges in the drug development and approval process. This ppt delves into the regulatory considerations associated with precision medicine, exploring the key aspects that pharmaceutical and biotechnology companies need to navigate
Emerging Technologies and Tools in Precision Medicine Research
Precision medicine has witnessed significant advancements with the integration of emerging technologies and innovative tools. This abstract explores the current landscape of precision medicine research, focusing on the role of cutting-edge technologies and tools in revolutionizing healthcare approaches.
Precision Medicine in Action: Case Studies and Success Stories
Precision medicine, an innovative approach tailoring medical treatment to individual characteristics, holds great promise for improved patient outcomes. In this paradigm, pharmacovigilance plays a crucial role in monitoring and ensuring the safety of personalized treatments. The integration of big data and artificial intelligence (AI) into pharmacovigilance practices becomes paramount for handling the complexities of individualized therapies and identifying potential safety concerns. This article explores the synergies between big data, AI, and pharmacovigilance in the context of precision medicine.
Harnessing Big Data and Artificial Intelligence for Pharmacovigilance in Prec...
Precision medicine, an innovative approach tailoring medical treatment to individual characteristics, holds great promise for improved patient outcomes. In this paradigm, pharmacovigilance plays a crucial role in monitoring and ensuring the safety of personalized treatments. The integration of big data and artificial intelligence (AI) into pharmacovigilance practices becomes paramount for handling the complexities of individualized therapies and identifying potential safety concerns. This article explores the synergies between big data, AI, and pharmacovigilance in the context of precision medicine.
Integration of Clinical Trial Systems: Enhancing Collaboration and Efficiency
Clinical trials are complex endeavors that involve numerous stakeholders, vast datasets, and intricate processes. To streamline operations, enhance collaboration, and improve efficiency, the integration of clinical trial systems has emerged as a pivotal solution. This strategic approach involves connecting various components, such as electronic data capture (EDC) systems, clinical trial management systems (CTMS), and electronic health records (EHR), fostering a cohesive ecosystem that accelerates the pace of research and ensures data accuracy.
Pharmacovigilance (PV) Companies: Ensuring Drug Safety in Personalized Treatm...
Pharmacovigilance, a critical component of the healthcare and pharmaceutical industry, plays a pivotal role in monitoring and ensuring the safety of drugs. As personalized treatment approaches gain prominence, the responsibilities of PV companies become even more significant. This article explores the key functions of pharmacovigilance companies in the context of personalized medicine, focusing on their role in ensuring drug safety and mitigating potential risks associated with tailored therapeutic interventions.
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Clinical trials play a pivotal role in advancing medical research and ensuring the efficacy of new treatments. In the context of precision medicine, where therapies are tailored to individual characteristics, adaptive design emerges as a powerful strategy to optimize clinical trial outcomes. This approach deviates from traditional fixed trial designs, allowing for modifications based on accumulating data, thus enhancing efficiency, flexibility, and the likelihood of success in precision medicine endeavors.
Artificial Intelligence In Clinical Trial
Clinical trials are a cornerstone of medical research, paving the way for new treatments and advancements in healthcare. In recent years, Artificial Intelligence (AI) has emerged as a transformative force, reshaping the landscape of clinical trials. This article explores the various ways in which AI is revolutionizing the design, execution, and analysis of clinical trials.
Emerging Technologies Shaping the Future of Precision Medicine
Precision medicine, with its focus on tailoring healthcare interventions to individual characteristics, is undergoing a transformative evolution propelled by emerging technologies. From advanced genomic tools to artificial intelligence, these technologies are revolutionizing our ability to understand, diagnose, and treat diseases at an unprecedented level of specificity. This article explores the key emerging technologies shaping the future of precision medicine.
Innovations in Liquid Biopsies for Precision Cancer Diagnosis
Precision medicine, with its focus on tailoring medical interventions to individual characteristics, benefits significantly from the integration of machine learning (ML) algorithms for predictive analytics. These algorithms analyze complex datasets, identify patterns, and generate predictions that inform personalized treatment strategies. This article explores the diverse applications of ML in precision medicine, highlighting the key algorithms driving predictive analytics in this transformative field.
More from ClinosolIndia (20)
Role of Drug Regulatory agencies in Clinical Research.
Role of Drug Regulatory agencies in Clinical Research.
ย
Clinical data security and Integrity in Clinical Research
Clinical data security and Integrity in Clinical Research
ย
Introduction to Blogs, Presentations and Review Articles- Noorush Shifa Nizami
Introduction to Blogs, Presentations and Review Articles- Noorush Shifa Nizami
ย
Patient-Centric Approaches in Precision Medicine Trials: Strategies for Success
Patient-Centric Approaches in Precision Medicine Trials: Strategies for Success
ย
Collaborative Initiatives: How Patient Advocacy Groups Contribute to the Succ...
Collaborative Initiatives: How Patient Advocacy Groups Contribute to the Succ...
ย
Ethical Dilemmas in Precision Medicine: Navigating the Intersection of Scienc...
Ethical Dilemmas in Precision Medicine: Navigating the Intersection of Scienc...
ย
Regulatory Considerations in Precision Medicine: Navigating the Approval Process
Regulatory Considerations in Precision Medicine: Navigating the Approval Process
ย
Emerging Technologies and Tools in Precision Medicine Research
Emerging Technologies and Tools in Precision Medicine Research
ย
Precision Medicine in Action: Case Studies and Success Stories
Precision Medicine in Action: Case Studies and Success Stories
ย
Harnessing Big Data and Artificial Intelligence for Pharmacovigilance in Prec...
Harnessing Big Data and Artificial Intelligence for Pharmacovigilance in Prec...
ย
Integration of Clinical Trial Systems: Enhancing Collaboration and Efficiency
Integration of Clinical Trial Systems: Enhancing Collaboration and Efficiency
ย
Pharmacovigilance (PV) Companies: Ensuring Drug Safety in Personalized Treatm...
Pharmacovigilance (PV) Companies: Ensuring Drug Safety in Personalized Treatm...
ย
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
ย
Emerging Technologies Shaping the Future of Precision Medicine
Emerging Technologies Shaping the Future of Precision Medicine
ย
Innovations in Liquid Biopsies for Precision Cancer Diagnosis
Innovations in Liquid Biopsies for Precision Cancer Diagnosis
ย
Recently uploaded
Discover the Perfect Way to Relax - Malayali Kerala Spa Ajman
Malayali Kerala Spa in Ajman, one among the top rated massage centre in ajman, welcomes you to experience high quality massage services from massage staffs from all ove rthe world! Being the best spa massage service providers, we take pride in offering traditional massage services of different countries, like
Indian Massage, Kerala Massage, Thai Massage, Pakistani Massage, Russian Massage etc
If you are seeking relaxation, pain relief, or wellness experience, our ajman spa is here for your unique needs and concerns. The services of our experienced therapists, and personalized attention will ensure that each visit will be memorable for you.
Book your appointment today and let us take you to a world of serenity and self-care. Because you deserves the best.
Bathinda โ๐๐๐ ๐พ๐๐ฃ๐๐ค 7742996321 โ๐๐๐ ๐พ๐๐ฃ๐๐ค Bathinda
Bathinda โ๐๐๐ ๐พ๐๐ฃ๐๐ค 7742996321 โ๐๐๐ ๐พ๐๐ฃ๐๐ค Bathindavarun0kumar00
Bathinda โ๐๐๐ ๐พ๐๐ฃ๐๐ค 7742996321 โ๐๐๐ ๐พ๐๐ฃ๐๐ค Bathindaย
Test bank clinical nursing skills a concept based approach 4e pearson educati...
Test bank clinical nursing skills a concept based approach 4e pearson educati...rightmanforbloodline
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson educationย
Call Girls Goa 7023059433 Celebrity Escorts Service in Goa
Call Girls Goa 7023059433 Celebrity Escorts Service in Goa
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
Emotional and Behavioural Problems in Children - Counselling and Family Thera...
Emotional and Behavioural Problems in Children - Counselling and Family Thera...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!ย
Test bank calculating drug dosages a patient safe approach to nursing and mat...
Test bank calculating drug dosages a patient safe approach to nursing and mat...rightmanforbloodline
Test bank calculating drug dosages a patient safe approach to nursing and math 2nd edition by castillo werner mccullough
Test bank calculating drug dosages a patient safe approach to nursing and math 2nd edition by castillo werner mccullough
Test bank calculating drug dosages a patient safe approach to nursing and math 2nd edition by castillo werner mcculloughย
Simple Steps to Make Her Choose You Every Day
Simple Steps to Make Her Choose You Every Day" and unlock the secrets to building a strong, lasting relationship. This comprehensive guide takes you on a journey to self-improvement, enhancing your communication and emotional skills, ensuring that your partner chooses you without hesitation. Forget about complications and start applying easy, straightforward steps that make her see you as the ideal person she can't live without. Gain the key to her heart and enjoy a relationship filled with love and mutual respect. This isn't just a book; it's an investment in your happiness and the happiness of your partner
PPT on Embryological and fetal development
Embryological development and fetal development
Factors influencing fetal development
About CentiUP - Introduction and Products.pdf
A heightened child formula, with the trio of Nano Calcium, HMO, and DHA mixed in the golden ratio, combined with NANO technology to help nourish the body deeply and comprehensively, helps children increase height, boost brain power, and improve the immune system and overall well-being.
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...The Lifesciences Magazine
The cyclothymia test is a pivotal tool in the diagnostic process. It helps clinicians assess the presence and severity of symptoms associated with cyclothymia.ย
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
Industrial Pharmacy -I, PCI syllabus
Psychological Safety as a Foundation for Improvement 12-06-24.pdf
Nick Holding and Pete Gordon's slides for an NHS IMAS (Interim Management and Support) webinar 'Psychological safety as a foundation for improvement'
Linga Mudra(Mark of Siva) generates excessive heat within the body
Benefits:
Linga mudra generates excessive heat within the body and is very useful for dealing with colds.
It also helps in boosting the immune system and makes the body more resistant to colds and similar infections.
The benefits of penis posture also extend to the respiratory system and it can help loosen the phlegm accumulated from the throat.
This posture also helps in weight loss.
Discomfort experienced in an air conditioned room is relieved by this mudra.
Difficulty in breathing can be relieved by this mudra.
Congested nose can be relieved by this mudra immediately and one can get good sleep.
It controls the flow of the menstrual cycle. Performing the Linga mudra with the Sun Mudra gives better results โ both 15 minutes each, one after the other.
When navel center is shifted from its original place, comes back to its place by this mudra.
Nursing management of the patient with Tonsillitis PPT
Prepared by Prof. Blessy Thomas MSc Nursing, FNCON, SPN. The tonsils are two small glands that sit on either side of the throat.
In young children, they help to fightย germs and act as a barrier against infection.
ย Tonsilsย act as filters, trapping germs that could otherwise enter the airways and cause infection.
They also make antibodies to fight infection.
But sometimes, they get overwhelmed by bacteria or viruses.
This can make them swollen and inflamed.
Tonsillitis is an infection of the tonsils, two masses of tissue at the back of the throat.
Tonsillitis isย inflammation of the tonsils, two oval-shaped pads of tissue at the back of the throat โ one tonsil on each side.
Tonsillitis is common, especially in children.
It can happen once in a while or come back again and again in a short period.Nursing management of Tonsillitis is important.
A comprehensive understanding of the operations for management of Tonsillitis and areas requiring special attention would be important.
PRESSURE INJURY CARE AND MANAGEMENT FOR HCW
Cme on pressure injury care.
Credit to : PPP Abdul Manan Bin Othman.
UNIT PERKEMBANGAN PROFESYEN PPP
BAHAGIAN PEMBANGUNAN KESIHATAN KELUARGA
Exosome Therapyโs Regenerative Effects on Skin and Hair Rejuvenation
Explore the transformative effects of exosome therapy on skin and hair rejuvenation. Learn how these tiny vesicles deliver essential growth factors and stimulate cellular repair, offering natural solutions for aging skin and hair loss. Discover the science behind exosomes and their benefits in aesthetic dermatology.
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
When it comes to creating marketing strategies that target older adults, it is crucial to have insight into their media habits and preferences. Understanding how older adults consume and use media is key to creating acquisition and retention strategies. We recently conducted our seventh annual survey to gain insight into the media preferences of older adults in 2024. Here are the survey responses and marketing implications that stood out to us.
Recently uploaded (20)
Discover the Perfect Way to Relax - Malayali Kerala Spa Ajman
Discover the Perfect Way to Relax - Malayali Kerala Spa Ajman
ย
Bathinda โ๐๐๐ ๐พ๐๐ฃ๐๐ค 7742996321 โ๐๐๐ ๐พ๐๐ฃ๐๐ค Bathinda
Bathinda โ๐๐๐ ๐พ๐๐ฃ๐๐ค 7742996321 โ๐๐๐ ๐พ๐๐ฃ๐๐ค Bathinda
ย
Test bank clinical nursing skills a concept based approach 4e pearson educati...
Test bank clinical nursing skills a concept based approach 4e pearson educati...
ย
Call Girls Goa 7023059433 Celebrity Escorts Service in Goa
Call Girls Goa 7023059433 Celebrity Escorts Service in Goa
ย
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...
ย
Emotional and Behavioural Problems in Children - Counselling and Family Thera...
Emotional and Behavioural Problems in Children - Counselling and Family Thera...
ย
Test bank calculating drug dosages a patient safe approach to nursing and mat...
Test bank calculating drug dosages a patient safe approach to nursing and mat...
ย
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...
Cyclothymia Test: Diagnosing, Symptoms, Treatment, and Impact | The Lifescien...
ย
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
Sunscreens, IP-I, Dr. M.N.CHISHTI, Asst Prof. Dept of Pharmaceutics, YBCCPA
ย
Psychological Safety as a Foundation for Improvement 12-06-24.pdf
Psychological Safety as a Foundation for Improvement 12-06-24.pdf
ย
Linga Mudra(Mark of Siva) generates excessive heat within the body
Linga Mudra(Mark of Siva) generates excessive heat within the body
ย
Nursing management of the patient with Tonsillitis PPT
Nursing management of the patient with Tonsillitis PPT
ย
Exosome Therapyโs Regenerative Effects on Skin and Hair Rejuvenation
Exosome Therapyโs Regenerative Effects on Skin and Hair Rejuvenation
ย
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...
ย
Clinical Research Interview Question Part 2
- 1. Interview Preparation Questions CLINICAL RESEARCH PART-2
- 2. 1 2 3 4 5 What is Unexpected Adverse Drug Reaction(UADR)? What is Audit? What is Protocol? What is Case Report Form (CRF)? What is Informed Consent Form? INDEX
- 3. Unexpected adverse drug reaction is an adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g., Investigatorโs Brochure foran unapproved investigational medicinal product or package of product characteristics for an approved product). What is UADR?
- 4. What is Audit? A systematic and independent examination of trial related activities and documents to determine whether the evaluated trial related activities were conducted, and the data were recorded, analyzed and accurately reported according to the protocol, sponsor's standard operating procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirements.
- 5. What is Protocol? A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. โข Protocol Amendment: A written description of a changes to or formal clarification of a protocol.
- 6. What is CRF? Case report form is an printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each trial subject.
- 7. What is ICF? A process by which a subject voluntarily confirms hisor her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form.